Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York. Show more

1500 Broadway, New York, NY, 10036, United States

https://www.nuvationbio.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.872B

52 Wk Range

$1.54 - $9.75

Previous Close

$5.46

Open

$5.52

Volume

4,836,137

Day Range

$5.35 - $5.76

Enterprise Value

719.9M

Cash

549M

Avg Qtr Burn

-52.89M

Insider Ownership

19.05%

Institutional Own.

63.06%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IBTROZI (Taletrectinib) (ROS1 inhibitor) Details ROS1-Positive Non-small cell lung carcinoma (NSCLC)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IBTROZI (Taletrectinib) Details ROS1-Positive Early-Stage Non-Small Cell Lung Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Safusidenib Details High-grade Glioma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUV-1511 Details Advanced solid tumors	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUV-868 +enzalutamide Details Solid tumor/s, Cancer, Castration-resistant prostate cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUV-868 +olaparib Details Solid tumor/s, Cancer, Ovarian cancer, Pancreatic cancer, Triple-negative breast cancer , Castration-resistant prostate cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUV-868 (BD2-Selective BETi) Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUV-422 (CDK inhibitor) Details High-grade Glioma , Solid tumor/s, Cancer, Prostate cancer, Breast cancer, Castration-resistant prostate cancer, Metastatic breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.